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Abstract
Background Cancer cachexia is a severe wasting syndrome
characterized by the progressive loss of lean body mass and
systemic inflammation. Inhibiting the signaling of the tran-
scription factor nuclear factor kappa B (NF-κB) largely pre-
vents cancer-induced muscle wasting in murine models. We
have previously shown the utility of Compound A, a highly
selective novel NF-κB inhibitor that targets the IκB kinase
complex, to provide clinical benefit in cancer-induced skeletal
muscle and cardiac atrophy.
Methods Using a metabolomics approach, we describe the
changes found between cachectic and noncachectic gastroc-
nemius muscles before and after Compound A treatment at
various doses.
Results Of the 234 metabolites in the gastrocnemius,
cachexia-induced changes in gastrocnemius metabolism
reset the steady-state abundances of 42 metabolites (p<
0.05). These changes, not evenly distributed across bio-
chemical categories, are concentrated in amino acids,
peptides, carbohydrates and energetics intermediates,
and lipids. The gastrocnemius glycolytic pathway is
markedly altered—changes consistent with tumor
Warburg physiology. This is the first account of a
Warburg effect that is not exclusively restricted to can-
cer cells or rapidly proliferating nonmalignant cells.
Cachectic gastrocnemius also displays tricarboxylic acid
cycle disruptions, signs of oxidative stress, and impaired
redox homeostasis. Compound A only partially rescues
the phenotype of the cachectic gastrocnemius, failing to
restore the gastrocnemius’ baseline metabolic profile.
Conclusions The findings in the present manuscript enu-
merate the metabolic consequences of cachexia in the gas-
trocnemius and demonstrate that NF-kB targeted treatment
only partly rescues the cachectic metabolic phenotype.
These data strengthen the previous findings from metabolo-
mic characterization of serum in cachectic animals, suggest-
ing that many of the metabolic alterations observed in the
blood originate in the diseased muscle. These findings pro-
vide significant insight into the complex pathophysiology of
cancer cachexia and provide objective criteria for evaluating
future therapeutics.
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1 Introduction
Cancer cachexia is a complex metabolic and nutritional
syndrome characterized by weight loss, loss of muscle and
adipose tissue, weakness affecting functional status, im-
paired immune system, and alterations in carbohydrate,
lipid, and protein metabolism [1–3]. Unlike starvation,
where lean mass is preserved, cancer cachexia is a progres-
sive wasting disorder with loss of skeletal and visceral
muscle, with or without fat, frequently associated with in-
flammation and insulin resistance [4, 5]. The syndrome is
correlated with increasing morbidity and mortality, along
with significant impairment of quality of life and response
to treatment [1, 6]. In fact, cancer cachexia is estimated to
occur in 50–80 % of cancer patients and accounts for 20–
30 % of all cancer-related deaths [7].
The C26 murine undifferentiated colon carcinoma model
of cancer cachexia has been used to elucidate the mecha-
nisms of the syndrome, which has been found to closely
parallel human disease [8–10]. Recent studies using this
model have identified a role for tumor release of proinflam-
matory cytokines such as IL-1, IL-6, and TNF-α in the
mechanism of striated muscle loss [11]. These cytokines
further activate transcription factor nuclear factor kappa B
(NF-κB), which upregulates the ubiquitin-dependent degra-
dation of the sarcomere leading to muscle atrophy [12]. Our
and others’ recent work has shown that pharmacological and
genetic inhibition of NF-κB is protective against cancer
cachexia-induced muscle atrophy [13–15]. Compound A
in particular is a highly selective and competitive NF-κB
inhibitor that targets the upstream NF-κB regulator IκB
kinase complex (IKK-β); this ensures that only acute
increases in NF-κB, and not basal NF-κB activities, are
affected [16]. There is evidence in the literature that com-
pound A induces resistance to skeletal muscle injury [17]
and is also cardioprotective against cancer cachexia-induced
cardiac atrophy and systolic dysfunction [14].
While the mechanisms underlying muscle wasting in can-
cer cachexia are being investigated, little is known about the
impact of this wasting on muscle properties including muscle
function, but also on its metabolic properties [18]. Recently,
metabolomics, or the systematic study of the small-molecule
metabolite profiles that specific cellular processes leave be-
hind, has been used to yield a better understanding of cancer
cachexia. For instance, we have shown that cancer cachectic
mice sera have a unique metabolic fingerprint that confirms
cancer cachexia as a distinct entity from a healthy state, other
wasting disorders, and cancer itself [19]. Similar studies are
aiming at discovering specific biomarkers of cancer cachexia.
In the present study, we sought to identify changes in cachec-
tic murine gastrocnemius muscle samples and the effect of
Compound A treatment, using multiple-platform mass spec-
trometry and nontargeted biochemical profiling.
In this study, we report multiple changes in the cachectic
gastrocnemius that are partially rescued with Compound A
treatment. These changes give insight into the mechanisms
of cancer cachexia. One change in particular, the Warburg-
like metabolic signature in the cachectic skeletal muscle, is
to our knowledge, the first evidence of the existence of such
activity in cells other than cancer cells or rapidly proliferat-
ing noncancerous cells.
2 Material and methods
2.1 Cell line
The cachexia-inducing transplantable C26 undifferentiated
colon carcinoma cell line was a kind gift from Dr. Denis
Guttridge (Columbus, OH, USA). The cells were maintained
as monolayers in culture flasks at 37 °C with 5 % CO2 in
culture medium which consisted of Roswell Park Memorial
Institute 1640 (Gibco, Rockville, MD, USA) supplemented
with 5 % fetal bovine serum (Hyclone, Logan, UT, USA) and
1 % penicillin/streptomycin (Gibco). Immediately before in-
jection, cells were trypsinized at approximately 80 % conflu-
ence, washed, and suspended in phosphate-buffered saline at a
concentration of 5×106cells/ml.
2.2 Experimental protocol
Thir ty-three male BALB/c mice (Charles River
Laboratories, Wilmington, MA, USA) were housed under
conventional conditions with constant temperature and hu-
midity and were maintained on a 12:12-h dark–light cycle.
Mice were housed in five animals per cage and were
allowed free access to standard diet and water. Treatment
of mice was in accordance with the guidelines of the
Institutional Animal Care and Use Committee. After being
allowed to acclimate to their new environment for 3 days
before beginning the study, the mice aged 43–63 days
(weight, 22–24 g) were randomly divided into five groups:
healthy control mice, tumor-bearing mice (dimethyl sulfox-
ide [DMSO] sham), and tumor-bearing plus the anti-
inflammatory drug Compound A (2, 5, or 10 mg/kg).
Body weight, tumor volume, and food consumption were
measured every other day from inoculation to completion of
the study. Tumor growth was assessed using calipers in two
orthogonal dimensions (x=shortest diameter, y=longest di-
ameter). Tumor volume was calculated using the following
formula: V ¼ p 6=ð Þ  x2y.
On day 0, the mice in tumor-bearing groups were injected
subcutaneously in the right flank with 100 μl (approximate-
ly 500,000 cells) of C26 undifferentiated colon carcinoma
cells. Beginning on day6, when tumors were first noticed,
untreated tumor-bearing mice received daily single
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intraperitoneal injections of sterile DMSO, while treated
tumor-bearing mice received injections of Compound A (a
highly selective novel NF-κB inhibitor with an anti-
inflammatory role) at 2, 5, or 10 mg/kg. On day17, when
the majority of tumor-bearing mice had a significant tumor
burden with clinical signs of cachexia, all mice were euthan-
ized. One animal in the tumor-bearing group was sacrificed
early due to tumor volume in excess of IUCAC guidelines.
A final total body weight measurement was obtained. Final
body weight was calculated by subtracting excised tumor
weight from the last total body weight measurement (weight
of mice with tumors intact). Tumor weight was measured
from the gross specimens harvested at the completion of the
study. Hind limbs were weighed separately as a measure-
ment of lean body mass. Tumors were resected, measured,
and weighed, and a total carcass weight (total body weight
minus the tumor weight) was calculated. Gastrocnemius
muscles and tumors were excised from each animal imme-
diately after sacrifice, snap frozen in liquid nitrogen, and
stored at −80 °C.
2.3 Metabolomic analysis
Biochemical profiling was performed using multiple plat-
form (ultra high-pressure liquid chromatography (UHPLC)
and gas chromatography (GC)) mass spectrometry technol-
ogy, as described [20–23]. Briefly, a broad array of small
molecule metabolites, irrespective of class (e.g., amino
acids, lipids, carbohydrates), was examined to measure bio-
chemical changes within samples. The nontargeted process
used single sample extraction followed by protein precipi-
tation to recover a diverse range of molecules (e.g., polar
and hydrophobic).
2.4 Metabolite identification
Metabolites were identified by automated comparison and
spectra fitting to a chemical standard library of experimentally
derived spectra as previously described [20–22]. Identification
of known chemical entities was based on comparison with
library entries of purified authentic chemical standards. Of the
metabolites, 243 were identified in gastrocnemius muscles
using this global biochemical profiling analysis.
2.5 Sample preparation
Frozen gastrocnemius tissues (100 mg) were thawed on ice,
combined with 0.5 mL of water and disaggregated using a
bead mill homogenizer (1,350 strokes/min for 5 min, Geno/
Grinder 200 (Glen Mills Inc., Clifton, NJ, USA)). An ali-
quot of each sample was extracted with methanol (0.4 mL)
containing the recovery standards as previously reported
[20]. After extraction, the sample was centrifuged and
supernatant removed using the MicroLab STAR® robotics
system. The extract supernatant was split into four equal
aliquots (0.11 mL each): two for UHPLC/mass spectrometry
(MS), one for GC/MS, and one reserve aliquot. Aliquots
were placed on a TurboVap® (Zymark) to remove solvent,
and dried under vacuum overnight. Samples were main-
tained at 4 °C throughout the extraction process. For
UHPLC/MS analysis, extract aliquots were reconstituted in
either 0.1 % formic acid for positive ion UHPLC/MS or
6.5 mM ammonium bicarbonate pH8.0 for negative ion
UHPLC/MS. For GC/MS analysis, aliquots were derivatized
using equal parts of N,O-bistrimethylsilyl-trifluoroacetamide
and a solvent mixture of acetonitrile/dichloromethane/cyclo-
hexane (541) with 5 % triethylamine at 60 °C for 1 h. The
derivatization mixture also contained a series of alkyl ben-
zenes for use as retention time markers.
2.6 GC/MS and UHPLC/MS/MS analysis
UHPLC/MS/MS analysis was performed on a Waters
Acquity UHPLC (Waters Corporation, Milford, MA, USA)
coupled to an linear trap quadrupole (LTQ) mass spectrom-
eter (Thermo Fisher Scientific Inc., Waltham, MA, USA)
equipped with an electrospray ionization source. Two sepa-
rate UHPLC injections were performed on each sample: one
optimized for positive ions and one for negative ions. The
mobile phase for positive ion analysis consisted of 0.1 %
formic acid in H2O (solvent A) and 0.1 % formic acid in
methanol (solvent B), while the mobile phase for negative
ion analysis consisted of 6.5 mM ammonium bicarbonate,
pH8.0 (solvent A) and 6.5 mM ammonium bicarbonate in
95 % methanol (solvent B). Acidic extracts were evaluated
for positive ions while basic extracts were evaluated for
negative ions in independent injections using dedicated
chromatographic columns (2.1×100 mm BEH C18 with
1.7 μm particle, Waters) maintained at 40 °C. The LTQ
alternated between full-scan mass spectra (99–1,000 m/z)
and data dependent MS/MS scans, which used dynamic
exclusion.
The derivatized samples were analyzed on a Thermo-
Finnigan Trace DSQ fast-scanning single–quadrupole MS
operated at unit mass resolving power. Separation occurred
through a temperature ramp (60–340 °C) using helium as a
carrier gas on a GC column (20 m×0.18 mm with 0.18 μm
film phase consisting of 5 % phenyldimethyl silicone). The
MS employed electron impact ionization with a 50–750 amu
scan range and was tuned and calibrated daily for mass
resolution and mass accuracy.
2.7 Data normalization
All samples were analyzed on a single day. For each metab-
olite, the raw area counts were divided by its median value.
J Cachexia Sarcopenia Muscle (2013) 4:145–155 147
Missing values were assumed to result from areas falling
below limits of detection. For each metabolite, missing
values were imputed with its observed minimum after the
normalization step.
2.8 Data extraction and quality assurance
Peaks were identified using Metabolon’s proprietary peak inte-
gration software and component parts were stored in a separate
and specifically designed complex data structure [24].
Process quality was evaluated by pooling an aliquot
(10 μL) of additional samples, each experimental sample
together to serve as a technical replicate for duration of the
run. This technical replicate sample was injected throughout
the platform run day, allowing variability in quantitation of
detected biochemicals to be monitored. With this monitor-
ing, a metric on overall process variability was assigned for
the platform’s performance (see “Results” section).
The median relative standard deviation (MRSD), a qual-
ity assurance metric of quantification and measure of instru-
ment variability, was determined to be 8 % for a panel of 30
internal standards [25]. Overall process variability (i.e., ex-
traction, recovery, resuspension, and instrument perfor-
mance) for endogenous biochemicals within technical
replicate samples was calculated to be 15 % MRSD. These
standard deviation values reflected acceptable levels of var-
iability for overall process and instrumentation of the ana-
lytical platform.
2.9 Statistical analysis
Statistical analyses were performed using JMP (JMP,
Version 8. SAS Institute Inc., Cary, NC, USA, 1989–2009)
and “R” (http://cran.r-project.org/).
3 Results
3.1 Metabolic derangements in the cachectic gastrocnemius
Of the 234 metabolites from all major biochemical catego-
ries that were found in the gastrocnemius, cachexia-induced
changes in gastrocnemius metabolism resulted in altering
the steady-state abundances of 42 of these metabolites,
either increasing or decreasing them compared to controls
(p<0.05, FDR=0.26; Fig. 1 and Electronic supplementary
material (ESM) 1). These changes were not evenly distrib-
uted across biochemical categories, but instead were con-
centrated in amino acids and peptides (15), carbohydrates
and energetics intermediates (14), and lipids (especially
medium chain fatty acids and polar lipid head groups, 12).
Further consequences of cachexia in the gastrocnemius
are biochemical signatures of oxidative and nitrogen
stresses. The oxidative stress can be observed in the deple-
tion of antioxidant peptides glutathione, anserine, and car-
nosine from diseased muscle (Fig. 2a). A further finding
supporting the increased oxidative stress or impaired redox
homeostasis in the cachectic muscle was the observation
that the mannitol/mannose ratio shifted toward the oxidized
form (mannitol/mannose ratio in the controls is 2.4±1.1
compared to 0.56±0.25 in the cachectic condition (p<
0.05).). Cachectic gastrocnemius also displays evidence of
increased nitrogen stress and glutamine reduction with in-
creased levels of the urea cycle intermediates, ornithine and
arginine, in cachectic gastrocnemius samples (Fig. 2b).
The gastrocnemius glycolytic pathway was markedly
altered during cachexia. Specifically, there was a dramatic
increase in the abundance of hexose-6-phosphates, includ-
ing glucose-6-phosphate, fructose-6-phosphate, and
mannose-6-phosphate (Fig. 3a). At the same time, there
was a marked decrease in the abundance of the phosphory-
lated, 3-carbon glycolytic fragments 3-phosphoglycerate, 2-
phosphoglycerate, and phosphoenolpyruvate (Fig. 3b).
Consistent with the rebalancing of glycolytic intermediates
in the cachectic gastrocnemius were findings that metabo-
lites related to glycolysis were also altered in cachexia.
Consistent with the decreased abundance of 3-carbon gly-
colytic fragments were reduced abundances of the amino
acids that are made from 3-carbon glycolytic fragments
(serine and glycine from 3-phosphoglycerate, and alanine
from pyruvate; Fig. 3c). The lower amount of 3-carbon
glycolytic intermediates was also reflected in a lower abun-
dance of citrate and malate, key intermediates in the tricar-
boxylic acid (TCA) cycle (Fig. 3d). Although those two
TCA cycle intermediates were decreased, there was a sig-
nificant increase in the abundance of succinylcarnitine, a
surrogate for the measurement of succinyl-CoA (Fig. 3d).
3.2 Anti-inflammatory treatment partially rescues the
metabolic phenotype of the cachectic gastrocnemius
Treatment with the anti-inflammatory agent Compound A
had a modest effect on the biochemistry of the cachectic
gastrocnemius. Of the 42 disease-associated changes, 11
were altered by treatment (ESM 1). Compound A treatment
restored the abundance of the antioxidant histidine dipep-
tides carnosine and anserine to control levels (Fig. 4a). Also,
galactitol, the product of aldose reductase-mediated reduc-
tion of galactose was partially rescued (Fig. 4a). Two of the
polar lipid head groups, ethanolamine and inositol-1-
phosphate also recovered to control levels with treatment
(Fig. 4b). Compound A treatment resulted in partial recov-
ery of energetics pathway metabolite levels; the glycolytic
hexose phosphates (glucose-6-phosphate and fructose-6-
phosphate) and citrate were brought back to their control
levels (Fig. 4c).
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4 Discussion
In this study, mice were inoculated with the C-26 murine
undifferentiated colon carcinoma, an established model that
results in muscle wasting that mimics clinical cancer-related
cachexia. This tumor cell line was previously shown to
cause significant loss of mass in gastrocnemius and extensor
digitorum longus muscles in mice without significant effects
on food intake [11, 14, 15, 19]. Thus, any muscle wasting
associated with this tumor cannot be attributed to anorexia
and altered energy intake.
Metabolomic analysis of gastrocnemius muscles from
animals with established cachexia revealed two predominant
effects of cancer cachexia: increased oxidative stress and a
disease-associated shift in glucose utilization through a high
rate of glycolysis. The latter is similar to the physiology
seen in tumor-related “Warburg effect.” An overview of the
alterations in both central carbon and nitrogen metabolism
in the cachectic gastrocnemius is shown in Fig. 5. Themetabolic
evidence of the redox imbalance in the cachectic gastrocnemius
was the depletion of glutathione, the reduced abundance of
antioxidant histidine dipeptides, and a shift in the ratios of
redox-related metabolites toward their oxidized forms.
Oxidative stress derives from an imbalance between pro-
duction and neutralization of reactive oxygen species (ROS)
and/or reactive nitrogen species (RNS) [26, 27]. Indicators of
ROS and RNS insults in skeletal muscle have been previously
reported to be increased both in animal models of cancer
cachexia [28, 29] and in cancer patients [30]. The ratio of
oxidized glutathione to reduced glutathione, as measured in
cachectic gastrocnemius samples, has been shown to be sig-
nificantly increased, along with a decrease of the antioxidant
enzyme superoxide dismutase activity [26].
ROS is known to cause damage to cellular components,
organelles, membranes, and individual proteins; many cell















































Fig. 1 Heat map of metabolite
abundance profiles showing
metabolic derangements in
cachectic gastrocnemius. Of the
234 metabolites in the
gastrocnemius, cachexia-
induced changes reset the
steady-state abundances of 42
metabolites (p<0.05). These
changes are not evenly distrib-
uted across biochemical cate-
gories. The gastrocnemius
glycolytic pathway is markedly
altered—changes consistent
with tumor Warburg physiolo-
gy. This is the first account of a
Warburg effect that is not ex-
clusively restricted to cancer
cells or rapidly proliferating
nonmalignant cells
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a cellular recycling program whereby damaged macromo-
lecular complexes are broken down into their component
parts for reuse. While there is considerable evidence sup-
porting autophagy in cardiac muscle, the data are not clear-
cut in skeletal muscle. Recently published electron
micrographs of skeletal muscle from cachectic mice docu-
ment electron lucent regions and swelling—ultrastructural
findings that are suggestive of autophagy [31]. One of the
autophagy triggers is a nutrient sensor signaling pathway
and elevated glutamine abundance has been found to stim-
ulate that pathway. However, in this study, glutamine was
found to decrease in the cachectic gastrocnemius.
Several investigators have recently found that cancer
cells can cause metabolic alterations in their surrounding
stromal cells, effectively catabolizing the resources within
the stroma to provide high-quality fuel sources for the tumor
[32]. In many systems, cancer-associated fibroblasts have
now been shown to have increased autophagy and actively
secrete glutamine for the adjacent tumor [33]. These data
suggest that cachexia-inducing tumors may be reprogram-
ming the metabolism of skeletal muscle to catabolize their
components for high-quality fuel sources, even though the
tumors are distant from the muscle. Further work will be
necessary to synthesize the present manuscript with these
findings and determine the role that autophagy may play in
this process.
ROS also leads to upregulation of the ubiquitin/protea-
some pathway through NF-κβ activation accelerating pro-
tein degradation and muscle mass loss [28, 34, 35].
Alterations in muscle energetics are also intimately linked
with tissue redox status and the pattern of glucose utilization
intermediates in the glycolytic pathway was significantly
altered in the cachectic gastrocnemius. The observed pat-
tern, an increase in hexose phosphates with a concomitant
decrease in 3-carbon glycolytic fragments, is similar to that
seen with the “Warburg effect” that has been extensively
studied in tumor metabolism. This study provides the first
evidence at the possibility of a Warburg-like metabolism in
skeletal muscle. Further studies are necessary in order to
determine whether these findings truly represent a Warburg-
like metabolism or are due to altered cellularity in the
muscle at this point in the disease process.
The present manuscript illustrates steady-state metabo-
lism in the cachectic gastrocnemius at a single time point in
disease progression. At this time point, there was already
significant muscle mass lost and damage to the molecular
components of the tissue has accumulated. Further work,
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Fig. 2 Boxplots illustrating the major observed alterations in oxidative and nitrogen stress in the cachectic gastrocnemius. a Markers associated with
redox state, b cationic amino acids
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Fig. 3 Box plots illustrating the major observed alterations to the
glycolytic and TCA pathways in the cachectic gastrocnemius. a Ele-
vation of hexose phosphates, b reduction in 3-carbon glycolytic
intermediates, c reduction of amino acids that are made from 3-
carbon glycolytic fragments, and d alteration in the abundance patterns
of TCA cycle intermediates
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ultrastructure and metabolism, could help to clarify the roles
of autophagy and metabolic reprogramming in skeletal
muscle that appear to occur in the presence of a cachexia-






































Detected, abundance increased 
(p < 0.05)
Detected, abundance increased 









Fig. 5 Overview of alterations
in both central carbon and
nitrogen metabolism in the
cachectic gastrocnemius.
Pronounced alterations
occurred in both central carbon
metabolism and nitrogen





phosphate and mannose accu-
mulated while the 3 carbon
glycolytic fragments and
metabolites derived from those
compounds (including the 3-
carbon amino acids serine and
alanine and TCA cycle inter-
mediates) decreased. At the
same time, the urea cycle inter-
mediates arginine and ornithine
significantly increased
carnosine anserinegalactitol (dulcitol)a
b inositol-1-phosphate (I1P) citrateethanolamine
Cachectic
Cachectic + 2 mg/kg Compound A
Cachectic + 5 mg/kg Compound A
Cachectic + 10 mg/kg Compound A
Control
c
Fig. 4 Box plots illustrating the major observed alterations in the cachectic gastrocnemius with or without Compound A treatment compared to
control. Compound A treatment effect on a markers associated with redox state, b polar lipid head groups, and c energetics pathway compounds
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which rely primarily on mitochondrial oxidative phosphor-
ylation to generate the energy needed for cellular processes,
most cancer cells instead rely on aerobic glycolysis [36].
This phenomenon enables rapidly dividing tumor cells to
generate essential biosynthetic building blocks such as
nucleic acids, amino acids, and lipids from glycolytic inter-
mediates to permit growth and duplication of cellular com-
ponents during division [37]. One consequence of the
rebalancing of glycolytic intermediates is the apparent
shunting of metabolism away from the TCA cycle and
consequently oxidative phosphorylation.
It is also noteworthy that a potential rationale for the
switch to a Warburg-like effect might be driven by skeletal
muscle satellite cells. In fact, there is evidence of increased
satellite cell proliferation during times of fiber wasting [38].
These cells might acquire a Warburg-like metabolism to
support rapid proliferation [39].
A further defect in cachectic muscle samples affects the
TCA cycle. Intermediates, such as citrate and malate were
also markedly reduced, whereas succinylcarnitine was in-
creased. These changes in TCA cycle intermediates suggest
that during cachexia there is less carbon flowing through the
TCA cycle and further suggest that the defect lies between
succinyl-CoA and malate. Three enzymes of the TCA cycle
are known to be sensitive to oxidative stress; namely aconi-
tase, α-ketoglutarate dehydrogenase, and succinate dehy-
drogenase, with varying sensitivities and consequences of
their impaired function [40, 41]. The reduced abundance of
3-carbon glycolytic intermediates and citrate suggest that
less substrate is entering the TCA cycle. The increased
abundance of succinylcarnitine in these same tissues indi-
cates that there is a defect in complex II activity that con-
tains succinate dehydrogenase and couples the TCA cycle
and oxidative phosphorylation.
Chronic inflammation in the context of cancer, such as
with cachexia, is mediated by proinflammatory cytokines
that are regulated by NF-κB, making the latter an ap-
pealing target for therapeutic intervention [42]. NF-κB
signaling is controlled by the inhibitor of IKK, a critical
catalytic subunit of which is IKK-β. Compound A is a
potent and selective IKK-β inhibitor and acts as a prom-
ising anti-inflammatory in vitro and in vivo [16]. Unlike
proteasome inhibitors which block basal NF-κB activity
[43] resulting in significant side effects and even lethal-
ity in humans [44], Compound A is focused on stress-
induced NF-κB activation, allowing sufficient basal NF-
κB activity to prevent apoptosis while still being suffi-
cient to limit the inflammatory activity of NF-κB [16].
Therefore, we hypothesized that Compound A treatment
would protect the gastrocnemius from cancer-induced
cachexia. What we observed was that the cachexia-
induced changes in the gastrocnemius were only partially
corrected with Compound A treatment.
Compound A is given systemically, allowing NF-κB
to be inhibited at the level of the heart, skeletal muscle,
or other organs. The effectiveness of NF-κB inhibition
due to Compound A treatment has been previously dem-
onstrated in the cardiac muscles of the same mice used
in this experiment [14]. NF-κB inhibition was deter-
mined using enzyme-linked immunosorbent assay for
NF-κB activity, but also with the expression of Nfkbia,
a gene regulated by NF-κB, as another surrogate of NF-
κB activity.
Among the changes affected by Compound A treatment
is the tissue redox environment of the gastrocnemius as
evidenced by the renormalization of anti-inflammatory his-
tidine dipeptides and polar lipid head groups. Also, galac-
titol, the product of aldose reductase-mediated reduction of
galactose was partially rescued, suggesting that there was
some NADPH available to mediate that reaction (as op-
posed to being utilized to facilitate glutathione recycling).
It is well known that at least some of the effects exerted by
oxidative stress are mediated by activation of the transcrip-
tion factor NF-κB [45]. NF-κB activation in cancer cachexia
has been shown in both murine models [15] and human
cancer patients [46]. Inhibition of NF-κB by Compound A
can explain the partial restoration of the normal oxidative
environment.
5 Conclusion
Cancer cachexia has multiple effects on the gastrocnemius
including increased oxidative stress and impaired redox
homeostasis, changed pattern of glycolytic metabolite abun-
dance consistent with tumor Warburg physiology, decreased
carbon flow through the TCA cycle, and reduced abundance
of amino acids. The failure to restore the baseline metabolic
profile of the gastrocnemius with this treatment, especially
the 3-carbon intermediates of glycolysis and amino acids,
suggests that NF-κB inhibition does not address the root of
the cachectic phenotype, but rather intervenes with signifi-
cant symptomology.
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